Moreover, it was shown that OX40 imaging using 64Cu-DOTA-AbOX40 as a contrast agent for PET predicted tumor responses with greater accuracy than both blood-based measurements for early response (i.e., Luminex analyses including interferon-γ, tumor necrosis factor α, MCP1, MIP1B etc.)and anatomical measurements in this mouse model. This evidence concerns the gene TNFRSF4 and neoplasm.